25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
4 citations
,
October 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
28 citations
,
March 2013 in “Journal of Investigative Dermatology” Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
83 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
19 citations
,
August 2019 in “Dermatologic therapy” Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.